# A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

> **NCT00389740** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 400 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** MK0217, /Duration of Treatment : 12 Months
- **DRUG:** Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months

## Key facts

- **NCT ID:** NCT00389740
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04-02
- **Primary completion:** 2003-01-16
- **Final completion:** 2003-01-16
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389740, "A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00389740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*